Sarcoma (Jan 2003)

Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group

  • John H. Edmonson,
  • Louise M. Ryan,
  • Carla I. Falkson,
  • David G. Hicks,
  • Ronald H. Blum

DOI
https://doi.org/10.1080/1357714031000114156
Journal volume & issue
Vol. 7, no. 1
pp. 9 – 11

Abstract

Read online

Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study.